Skip to Content

AstraZeneca PLC ADR AZN

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


AstraZeneca Posts Solid Fourth Quarter, and Growth Outlook Continues to Look Strong

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

AstraZeneca reported fourth-quarter results that were slightly ahead of our and company-reported consensus expectations, but we don’t expect to make any major changes to our fair value estimate based on the minor outperformance. Astra looks moderately undervalued, with the market not likely fully appreciating the firm’s recently launched drugs, an improving operating margin structure, and a strong lineup of new drugs, all of which also support the firm’s wide moat rating.

Read Full Analysis

Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type
Employees 76,100